GSK3B and breast carcinoma: This action has been attributed to its ability to impede the AKT/GSK-3β pathway, evidenced by reductions in p-AKT, p-GSK-3β, and β-catenin levels, leading to suppression of breast cancer cell proliferation, migration, invasion, and induction of apoptosis [24].